STOCK TITAN

[Form 4] Generation Bio Co. Insider Trading Activity

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
4

Generation Bio (GBIO) Chief Scientific Officer reported routine equity transactions on 10/15/2025. 114 shares of common stock were issued upon settlement of restricted stock units (code M), and 34 shares were withheld to cover taxes at $6.71 per share (code F). Following these transactions, the officer directly owned 14,138 common shares.

The filing notes a one-for-10 reverse stock split effected on July 21, 2025. The RSU grant from January 20, 2023 vests over four years; 573 RSUs remained beneficially owned after the reported activity.

Generation Bio (GBIO) Chief Scientific Officer ha riportato transazioni azionarie ordinarie di routine il 15/10/2025. 114 azioni ordinarie sono state emesse al regolamento di unità azionarie vincolate (RSU) (codice M), e 34 azioni sono state trattenute per coprire le tasse a 6,71 $ per azione (codice F). A seguito di queste operazioni, l dirigente possedeva direttamente 14.138 azioni ordinarie.

La documentazione riporta uno scissione azionaria inversa di 1 per 10 avvenuta il 21 luglio 2025. Il conferimento RSU del 20 gennaio 2023 matura in quattro anni; 573 RSU restavano detenute beneficiariamente dopo l’attività riportata.

Generation Bio (GBIO) El Director de Ciencias (Chief Scientific Officer) informó sobre transacciones de acciones rutinarias el 15/10/2025. 114 acciones ordinarias se emitieron al liquidarse unidades de acciones restringidas (código M), y 34 acciones se retuvieron para cubrir impuestos a 6,71 $ por acción (código F). Tras estas operaciones, el directivo poseía directamente 14.138 acciones ordinarias.

El registro indica una división de acciones inversa de 1 por 10 efectuada el 21 de julio de 2025. La concesión de RSU del 20 de enero de 2023 vence a lo largo de cuatro años; 573 RSU quedaban efectivamente poseídas tras la actividad reportada.

Generation Bio (GBIO) 최고 과학책임자(CSO)가 2025년 10월 15일의 정기적인 지분 거래를 보고했습니다. 제한 주식 단위(RSU) 정산 시 보통주 114주가 발행되었고(코드 M), 세금을 충당하기 위해 주당 6.71달러로 34주가 보류되었습니다(코드 F). 이러한 거래 이후 해당 임원은 직접 14,138주의 보통주를 소유하게 되었습니다.

공시는 2025년 7월 21일에 시행된 10대1의 주식 분할(역분할)을 언급합니다. 2023년 1월 20일의 RSU 부여는 4년에 걸쳐 가속 vesting되며; 보고된 거래 이후 573RSU가 실제로 보유되어 있었습니다.

Generation Bio (GBIO) Le Directeur scientifique en chef a rapporté des transactions sur actions ordinaires courantes le 15/10/2025. 114 actions ordinaires ont été émises lors du règlement des unités d’actions restreintes (code M), et 34 actions ont été retenues pour couvrir les impôts à 6,71 $ par action (code F). Suite à ces transactions, le dirigeant détenait directement 14 138 actions ordinaires.

Le dépôt indique une division inverse d’actions de 1 pour 10 effectuée le 21 juillet 2025. L’attribution de RSU du 20 janvier 2023 vest sur quatre ans; 573 RSU restaient détenues de manière bénéficiaire après l’activité signalée.

Generation Bio (GBIO) Chief Scientific Officer berichtete routinemäßige Aktientransaktionen am 15.10.2025. 114 Stammaktien wurden bei der Abwicklung von Restricted Stock Units (RSU, Code M) ausgegeben, und 34 Aktien wurden einbehalten, um Steuern in Höhe von 6,71 USD pro Aktie (Code F) abzudecken. Nach diesen Transaktionen besaß der Beamte direkt 14.138 Stammaktien.

Die Einreichung vermerkt eine rückwirkende 1-für-10-Split-Aktienaufteilung, die am 21. Juli 2025 durchgeführt wurde. Die RSU-Zuteilung vom 20. Januar 2023 vestet über vier Jahre; 573 RSUs blieben nach der gemeldeten Aktivität vorteilhaft besessen.

Generation Bio (GBIO) رئيس القسم العلمي التنفيذي أبلغ عن معاملات أسهم روتينية في 15/10/2025. تم إصدار 114 سهمًا من الأسهم العادية عند تسوية وحدات الأسهم المقيدة (الرمز M)، وتم حجز 34 سهماً لتغطية الضرائب بمعدل 6.71 دولارًا للسهم (الرمز F). عقب هذه المعاملات، امتلك المسؤول مباشرة 14,138 سهماً عاديّاً.

تذكر الوثائق إجراء تقسيم عكسي للأسهم بمقدار 1 مقابل 10 في 21 يوليو 2025. منح RSU من 20 يناير 2023 يتأتى خلال أربع سنوات؛ 573 RSU بقيت مملوكة بطريقة مفيدة بعد النشاط المبلغ عنه.

Generation Bio (GBIO) 首席科学官在2025年10月15日报告了常规股权交易。 通过结算受限股票单位(RSU,代码M)发行了114股普通股,另有34股股份被扣留用于覆盖每股6.71美元的税费(代码F)。在这些交易之后,该官员直接持有14,138股普通股。

文件提到于2025年7月21日实施了1股转为10股的反向股票分割。2023年1月20日的RSU授予将在四年内归属;报告的交易后仍实际持有573股RSU。

Positive
  • None.
Negative
  • None.

Generation Bio (GBIO) Chief Scientific Officer ha riportato transazioni azionarie ordinarie di routine il 15/10/2025. 114 azioni ordinarie sono state emesse al regolamento di unità azionarie vincolate (RSU) (codice M), e 34 azioni sono state trattenute per coprire le tasse a 6,71 $ per azione (codice F). A seguito di queste operazioni, l dirigente possedeva direttamente 14.138 azioni ordinarie.

La documentazione riporta uno scissione azionaria inversa di 1 per 10 avvenuta il 21 luglio 2025. Il conferimento RSU del 20 gennaio 2023 matura in quattro anni; 573 RSU restavano detenute beneficiariamente dopo l’attività riportata.

Generation Bio (GBIO) El Director de Ciencias (Chief Scientific Officer) informó sobre transacciones de acciones rutinarias el 15/10/2025. 114 acciones ordinarias se emitieron al liquidarse unidades de acciones restringidas (código M), y 34 acciones se retuvieron para cubrir impuestos a 6,71 $ por acción (código F). Tras estas operaciones, el directivo poseía directamente 14.138 acciones ordinarias.

El registro indica una división de acciones inversa de 1 por 10 efectuada el 21 de julio de 2025. La concesión de RSU del 20 de enero de 2023 vence a lo largo de cuatro años; 573 RSU quedaban efectivamente poseídas tras la actividad reportada.

Generation Bio (GBIO) 최고 과학책임자(CSO)가 2025년 10월 15일의 정기적인 지분 거래를 보고했습니다. 제한 주식 단위(RSU) 정산 시 보통주 114주가 발행되었고(코드 M), 세금을 충당하기 위해 주당 6.71달러로 34주가 보류되었습니다(코드 F). 이러한 거래 이후 해당 임원은 직접 14,138주의 보통주를 소유하게 되었습니다.

공시는 2025년 7월 21일에 시행된 10대1의 주식 분할(역분할)을 언급합니다. 2023년 1월 20일의 RSU 부여는 4년에 걸쳐 가속 vesting되며; 보고된 거래 이후 573RSU가 실제로 보유되어 있었습니다.

Generation Bio (GBIO) Le Directeur scientifique en chef a rapporté des transactions sur actions ordinaires courantes le 15/10/2025. 114 actions ordinaires ont été émises lors du règlement des unités d’actions restreintes (code M), et 34 actions ont été retenues pour couvrir les impôts à 6,71 $ par action (code F). Suite à ces transactions, le dirigeant détenait directement 14 138 actions ordinaires.

Le dépôt indique une division inverse d’actions de 1 pour 10 effectuée le 21 juillet 2025. L’attribution de RSU du 20 janvier 2023 vest sur quatre ans; 573 RSU restaient détenues de manière bénéficiaire après l’activité signalée.

Generation Bio (GBIO) Chief Scientific Officer berichtete routinemäßige Aktientransaktionen am 15.10.2025. 114 Stammaktien wurden bei der Abwicklung von Restricted Stock Units (RSU, Code M) ausgegeben, und 34 Aktien wurden einbehalten, um Steuern in Höhe von 6,71 USD pro Aktie (Code F) abzudecken. Nach diesen Transaktionen besaß der Beamte direkt 14.138 Stammaktien.

Die Einreichung vermerkt eine rückwirkende 1-für-10-Split-Aktienaufteilung, die am 21. Juli 2025 durchgeführt wurde. Die RSU-Zuteilung vom 20. Januar 2023 vestet über vier Jahre; 573 RSUs blieben nach der gemeldeten Aktivität vorteilhaft besessen.

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Samayoa Phillip

(Last) (First) (Middle)
C/O GENERATION BIO CO.
301 BINNEY STREET, SUITE 401

(Street)
CAMBRIDGE MA 02142

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
Generation Bio Co. [ GBIO ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
CHIEF SCIENTIFIC OFFICER
3. Date of Earliest Transaction (Month/Day/Year)
10/15/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 10/15/2025 M 114(1) A (2) 14,172(1) D
Common Stock 10/15/2025 F 34(1) D $6.71 14,138(1) D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Restricted Stock Units (2) 10/15/2025 M 114(1) (3) (3) Common Stock 114(1) $0 573(1) D
Explanation of Responses:
1. Amounts reported in this Form 4 reflect the one-for-10 reverse stock split effected by the issuer on July 21, 2025.
2. Each restricted stock unit represents the right to receive one share of the company's common stock.
3. On January 20, 2023, the reporting person was granted 1,834 restricted stock units. The shares underlying the restricted stock units vest over four years, with 25% of the shares vested on January 15, 2024 and the remaining shares vesting in equal quarterly installments thereafter.
/s/ Shawna-Gay White, Attorney-in-Fact 10/17/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
Generation Bio Co.

NASDAQ:GBIO

GBIO Rankings

GBIO Latest News

GBIO Latest SEC Filings

GBIO Stock Data

44.72M
5.77M
14.24%
62.31%
2.9%
Biotechnology
Pharmaceutical Preparations
Link
United States
CAMBRIDGE